Hologic Newswire (Page 6)

Hologic Newswire (Page 6)

Comprehensive Real-Time News Feed for Hologic. (Page 6)

Results 101 - 120 of 1,246 in Hologic

  1. Increased Fetal Fibronectin (fFN) Testing in Pregnant Women Could Help Guide Better Patient CareRead the original story

    Oct 12, 2017 | Health News Digest

    MARLBOROUGH, Mass., - A new study found that women with symptoms of preterm labor who were discharged from the hospital without a fetal fibronectin test were more likely to deliver their baby prematurely within three days compared to women who were discharged with an fFN test, Hologic, Inc. announced today. The , published this week in the journal ClinicoEconomics and Outcomes Research , is one of the largest to evaluate interventions and outcomes in women presenting with symptoms of preterm labor.

    Comment?

  2. Hologic, Inc. (HOLX) Shares Sold by Virtu KCG Holdings LLCRead the original story w/Photo

    Oct 11, 2017 | IntersportsWire

    Virtu KCG Holdings LLC trimmed its holdings in Hologic, Inc. by 65.4% during the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 10,958 shares of the medical equipment provider's stock after selling 20,747 shares during the period.

    Comment?

  3. Hologic, Inc. (HOLX) Receives "Buy" Rating from Jefferies Group LLCRead the original story w/Photo

    Oct 10, 2017 | AmericanBankingNews.com

    ... about the company. Piper Jaffray Companies reaffirmed a "buy" rating and set a $51.00 price target on shares of Hologic in a report on Friday, July 14th. Deutsche Bank AG dropped their price target on Hologic from $51.00 to $49.00 and set a "buy" ...

    Comment?

  4. Voya Investment Management LLC Sells 974,702 Shares of Hologic, Inc.Read the original story w/Photo

    Oct 10, 2017 | IntersportsWire

    Voya Investment Management LLC lowered its stake in shares of Hologic, Inc. by 85.2% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 168,859 shares of the medical equipment provider's stock after selling 974,702 shares during the quarter.

    Comment?

  5. Hologic, Inc. (HOLX) Receives Average Recommendation of "Hold" from BrokeragesRead the original story w/Photo

    Oct 8, 2017 | AmericanBankingNews.com

    Hologic, Inc. has received an average recommendation of "Hold" from the fifteen ratings firms that are covering the stock, MarketBeat Ratings reports. Two analysts have rated the stock with a sell recommendation, four have assigned a hold recommendation and nine have given a buy recommendation to the company.

    Comment?

  6. Dimensional Fund Advisors LP Buys 306,297 Shares of Hologic, Inc.Read the original story w/Photo

    Oct 7, 2017 | IntersportsWire

    Dimensional Fund Advisors LP raised its stake in shares of Hologic, Inc. by 19.7% in the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 1,863,666 shares of the medical equipment provider's stock after buying an additional 306,297 shares during the quarter.

    Comment?

  7. Hologic, Inc. (HOLX) Cut to Sell at Zacks Investment ResearchRead the original story w/Photo

    Oct 6, 2017 | Daily Political

    According to Zacks, "Hologic is optimistic about the recent commercial launch of the Brevera breast biopsy system in the United States. Hologic's third-quarter 2017 performance was quite promising with revenues and earnings beating the estimates.

    Comment?

  8. Analysts Anticipate Hologic, Inc. (HOLX) Will Post Earnings of $0.49 Per ShareRead the original story w/Photo

    Oct 6, 2017 | IntersportsWire

    Analysts expect Hologic, Inc. to post $0.49 earnings per share for the current quarter, Zacks reports. Seven analysts have issued estimates for Hologic's earnings.

    Comment?

  9. Increased fFN testing could help provide better care for women with symptoms of preterm laborRead the original story w/Photo

    Oct 6, 2017 | Medical News

    Increased fFN testing could improve care management by preventing more women with symptoms of preterm labor from being discharged from the hospital too soon A new study found that women with symptoms of preterm labor who were discharged from the hospital without a fetal fibronectin test were more likely to deliver their baby prematurely compared to women who were discharged with an fFN test, Hologic, Inc. announced today. The study, published this week in the journal ClinicoEconomics and Outcomes Research , is one of the largest to evaluate interventions and outcomes in women presenting with symptoms of preterm labor.

    Comment?

  10. Panther Fusion Flu A/B/RSV Assay Now FDA Cleared on Hologic's New Panther Fusion SystemRead the original story

    Oct 5, 2017 | BioSpace

    The Panther Fusion is available as a full system or the Panther Fusion module can be attached to existing Panther systems in the field to extend testing capabilities. Specifically, the Panther Fusion adds the capacity to run PCR assays in addition to tests based on TMA , the proprietary Hologic chemistry that powers the Company's AptimaA brand.

    Comment?

  11. Hologic prices $350M debt offering at parRead the original story w/Photo

    Oct 5, 2017 | Seeking Alpha

    Hologic prices its $350M aggregate principal amount of 4.375% senior notes due 2025 at par.

    Comment?

  12. Hologic Announces Offering of $350 Million of Senior Notes Due 2025Read the original story

    Oct 4, 2017 | PressReleasePoint

    Hologic intends to use the proceeds of the offering and available cash, including funds from its new five-year secured credit agreement, to retire the Company's remaining convertible notes, including through repurchases or redemptions, when they become callable in December of 2017 and March of 2018. The 2025 notes will not be registered under the Securities Act of 1933, as amended, or any state securities laws.

    Comment?

  13. Hologic To Announce Financial Results For The Fourth Quarter Of...Read the original story

    Oct 3, 2017 | BioSpace

    /PRNewswire/ -- Hologic, Inc. (Nasdaq: HOLX) announced today that the Company plans to release its financial results for the fourth quarter of fiscal 2017 on ) or +1 323-794-2093 (for international callers) and referencing access code 7397739. ...

    Comment?

  14. Hologic, Inc. (HOLX) Downgraded to Sell at Zacks Investment ResearchRead the original story w/Photo

    Oct 3, 2017 | AmericanBankingNews.com

    According to Zacks, "Hologic is optimistic about the recent commercial launch of the Brevera breast biopsy system in the United States. Hologic's third-quarter 2017 performance was quite promising with revenues and earnings beating the estimates.

    Comment?

  15. Hologic, Inc. (HOLX) Given Buy Rating at Needham & Company LLCRead the original story w/Photo

    Oct 2, 2017 | AmericanBankingNews.com

    ... reports on the company. Piper Jaffray Companies restated a "buy" rating and set a $51.00 price target on shares of Hologic in a research note on Friday, July 14th. Stifel Nicolaus reaffirmed a "buy" rating on shares of Hologic in a research report ...

    Comment?

  16. Hologic, Inc. (HOLX) Shares Bought by Picton Mahoney Asset ManagementRead the original story w/Photo

    Oct 1, 2017 | IntersportsWire

    Picton Mahoney Asset Management boosted its position in Hologic, Inc. by 8.1% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 57,150 shares of the medical equipment provider's stock after acquiring an additional 4,300 shares during the quarter.

    Comment?

  17. Hologic Introduces a More Comfortable Mammogram with the Launch of...Read the original story w/Photo

    Sep 29, 2017 | Newkerala.com

    MARLBOROUGH, Mass: Hologic, Inc. today announced the commercial availability of its new SmartCurve breast stabilization system, which has been clinically proven to deliver a more comfortable mammogram without compromising image quality, workflow or dose. The SmartCurve system is available exclusively with Hologic's Genius 3D Mammography exam, the only mammogram that detects more invasive cancers, reduces false positives, and is FDA approved as superior to conventional 2D mammography for all women, including those with dense breasts.2,3,4 For years, women have reported avoiding regular mammograms due in large part to the fear of discomfort associated with breast compression.

    Comment?

  18. Hologic CEO Steve MacMillan to Ring Nasdaq Opening Bell on October 2...Read the original story

    Sep 29, 2017 | PressReleasePoint

    Hologic is ringing the bell for the 12th consecutive year to celebrate the Company's recent advances in breast cancer screening and intervention, and to underscore an ongoing commitment to innovation in breast health. Hologic is primarily focused on improving women's health and well-being through early detection and treatment, and is an established leader in breast cancer diagnosis.

    Comment?

  19. Hologic, Inc. (Nasdaq: HOLX) to Ring The Nasdaq Stock Market Opening BellRead the original story w/Photo

    Sep 29, 2017 | GlobeNewswire

    What: Hologic, Inc. , an innovative medical technology company primarily focused on improving women's health and well-being through early detection and treatment, will visit the Nasdaq MarketSite in Times Square in conjunction with the start of Breast Cancer Awareness Month. The Company's recent advances in breast cancer screening and intervention underscore an ongoing commitment to innovation in breast health.

    Comment?

  20. Hologic, Inc. (HOLX) Shares Bought by Teachers Retirement System of The State of KentuckyRead the original story w/Photo

    Sep 27, 2017 | Daily Political

    Teachers Retirement System of The State of Kentucky raised its stake in Hologic, Inc. by 2.1% in the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 185,878 shares of the medical equipment provider's stock after purchasing an additional 3,893 shares during the period.

    Comment?